Eagle Biologics Overview
- Founded
-
2013
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$78.2M
Eagle Biologics General Information
Description
Operator of a biopharmaceutical agency intended to develop innovative protein formulation. The company's biopharmaceutical agency produces high-concentration drugs and related products with low viscosity, suitable for small-volume subcutaneous injection, enabling clients to avail improved access to highly viscous protein therapeutics.
Contact Information
Website
www.arsiarx.com
Formerly Known As
Arsia Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Delivery
Acquirer
Primary Office
- Kendall Square
- Cambridge, MA
- United States
Eagle Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 16-Nov-2016 | $78.2M | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Eagle Biologics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical agency intended to develop innovative protein formulation. The company's biopharmaceutic
Biotechnology
Cambridge, MA
00.00
0000-00-00
000000&0
000000
ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
0000000000000
Sheffield, United Kingdom
000000000000
000000
ctetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim a
0000 000000000
Little Chesterford, United Kingdom
00
As of 0000
000.00
00.00
0000-00-00
00000000
000.00
Add Comparison
Eagle Biologics Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protein Ark | Private Equity-Backed | Sheffield, United Kingdom | 000000000000 | |||
| 000000 | Formerly VC-backed | Little Chesterford, United Kingdom | 00 | 000.00 | 00000000 | 000.00 |
| 000000000 00000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00000 | 0000000000 0 | 00000 |
| 00000 | Formerly VC-backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Didcot, United Kingdom | 0 | 00000 | 0000000000 0 | 00000 |
Eagle Biologics Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Charles Wescott Ph.D | Vice President of Research & Development | ||
| Alexander Klibanov | Co-Founder | ||
| Robert Langer | Co-Founder |
Eagle Biologics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | 000 0000 | 000000 0 | ||
| Polaris Partners | Venture Capital | Minority | 000 0000 | 000000 0 |